<DOC>
	<DOCNO>NCT01014468</DOCNO>
	<brief_summary>To report short term anatomic visual acuity response intravitreal injection bevacizumab ranibizumab patient choroidal neovascularization secondary age-related macular degeneration .</brief_summary>
	<brief_title>Bevacizumab Versus Ranibizumab Age Related Macular Degeneration</brief_title>
	<detailed_description>We conduct retrospective study 500 eye choroidal neovascularization secondary age-related macular degeneration treat least two ( initial one month ) intravitreal injection 1.25 mg bevacizumab 0.5 mg ranibizumab follow-up least 3 month . Patients underwent Snellen visual acuity testing , optical coherence tomography ( OCT ) image ophthalmoscopic examination baseline follow-up visit .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age â‰¥ 50 year Active primary recurrent subfoveal lesion CNV secondary AMD Prior treatment intravitreal drug study eye Prior treatment verteporfin photodynamic therapy study eye Prior treatment systemic bevacizumab Prior treatment intravitreal drug verteporfin photodynamic therapy nonstudy eye within 3 moth study entry Laser photocoagulation within 1 month study entry study eye Previous participation clinical trial within 1 month entry study Subfoveal fibrosis atrophy study eye CNV either two eye due cause AMD histoplasmosis pathological myopia Retinal pigment epithelial tear involve macula study eye Any concurrent intraocular condition study eye could either require medical surgical intervention 12 month study period could contribute loss best correct visual acuity 12 month study period ( e.g . diabetic retinopathy , cataract , uncontrolled glaucoma ) . The decision exclusion base opinion local principal investigator . Active intraocular inflammation Vitreous hemorrhage study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>AMD</keyword>
	<keyword>Complications</keyword>
	<keyword>Visual acuity</keyword>
	<keyword>OCt</keyword>
	<keyword>Age Macular Degeneration</keyword>
</DOC>